Data supporting the involvement of XIAP in TRAIL resistance suggests that neutralizing XIAP might be critical for TRAIL sensitivity and an attractive target for potential combinatory therapy in the treatment of ‘type 2’ cancer cells. The gene discussed is XIAP; the disease is cancer.